Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Aug 28:8:73.
doi: 10.1186/1471-244X-8-73.

The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial

Yves Chaput  1 , Annick Magnan, Alain Gendron
Affiliations
Randomized Controlled Trial

The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial

Yves Chaput et al. BMC Psychiatry. .

Abstract

Background: Patients with major depression refractory to repeated pharmacological trials (TRD) may remain symptomatic for many years after their index episode. Augmentation strategies (with lithium or an atypical antipsychotic) or combining an antidepressant with short-term psychotherapy have been used with relative success in these patients. The aim of this study was to assess the effectiveness of the concomitant administration of quetiapine, an atypical antipsychotic, or placebo, to cognitive-behavior therapy (CBT) in TRD.

Methods: Thirty-one patients who met entrance criteria for unipolar major depression (TRD stage II or greater) underwent 3 weeks of lithium augmentation after which non-responders (N = 22) were randomized to receive either quetiapine or placebo as an adjunct to their 12 weekly CBT sessions (quetiapine/CBT or placebo/CBT groups). Primary efficacy measures were the Hamilton and the Montgomery-Asberg rating scales for depression.

Results: Overall, there was a significant reduction in both primary efficacy measure scores at LOCF for the 11 patients in the quetiapine/CBT group but not in the placebo/CBT treated patients. Patients in the quetiapine/CBT group, compared to those receiving placebo/CBT, showed a significantly greater degree of improvement on one primary and one secondary efficacy measure, were more likely to complete the trial and, completed a greater number of CBT sessions.

Conclusion: Although preliminary, our results suggest that the adjunctive administration of quetiapine to CBT may prove useful in the treatment of stage II TRD.

Trial registration: Current Controlled Trials ISRCTN12638696.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design and patient flow.
See this image and copyright information in PMC

References

    1. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007;52:46–54. - PubMed
    1. Huynh NN, McIntyre RS. What are the implications of the STAR*D trial for primary care? Prim Care Companion J Clin Psychiatry. 2008;10:91–96. - PMC - PubMed
    1. Bauer M, Adli M, Baethge C, Berghöfer A, Sasse J, Heinz A, Bschor T. Lithium augmentation in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry. 2003;48:440–8. - PubMed
    1. deMontigny C, Chaput Y, Blier P. Lithium augmentation of antidepressant treatments: evidence for the involvement of the 5-HT system? In: Briley M, Filion G, editor. New Concepts in depression. London MacMillan Press; 1988. pp. 144–160.
    1. Marangell LB. Swtiching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62 Suppl 18:12–7. - PubMed

Publication types

Associated data

LinkOut - more resources